findmyKOL
Clinical trialNCT04818632CompletedPhase 1Interventional

AZD9833 China PK Study

SponsorAstraZenecaEnrollment28ER+, HER2-, Metastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jian Zhang

    Department of Medical Oncology, Fudan University Shanghai Cancer Center

    Principal Investigator
  • Jiong Wu

    Department of Breast Surgery, Fudan University Shanghai Cancer Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Shanghai, China

  • Research Site

    Wuhan, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Nov 2021
Primary completion
7 Sept 2023
Completion
7 Sept 2023
Last update posted
17 Dec 2024
Registered enrollment
28
Registry id
NCT04818632

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.